| 0 (0%) | 04-14 09:56 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 19.93 | 1-year : | 23.28 |
| Resists | First : | 17.06 | Second : | 19.93 |
| Pivot price | 14.52  |
|||
| Supports | First : | 14.52 | Second : | 12.94 |
| MAs | MA(5) : | 15.25 |
MA(20) : | 14.43 |
| MA(100) : | 13.56 |
MA(250) : | 8.54 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.5 |
| %K %D | K(14,3) : | 74.9 |
D(3) : | 78.6 |
| RSI | RSI(14): 52.2 |
|||
| 52-week | High : | 26.95 | Low : | 3.01 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ CRVS ] has closed below upper band by 16.6%. Bollinger Bands are 56.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 8 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 15.66 - 15.73 | 15.73 - 15.8 |
| Low: | 14.81 - 14.9 | 14.9 - 14.98 |
| Close: | 15.03 - 15.16 | 15.16 - 15.29 |
Wed, 08 Apr 2026
Corvus Pharmaceuticals: Strong Clinical Narrative, Already Priced For Success - Seeking Alpha
Thu, 26 Mar 2026
Vanguard amends ownership for Corvus Pharmaceuticals (NASDAQ: CRVS) after realignment - Stock Titan
Wed, 18 Mar 2026
Is Corvus Pharmaceuticals’ Expanded US$200 Million ATM Facility Reframing Its Funding Story for CRVS? - simplywall.st
Thu, 12 Mar 2026
CORVUS PHARMACEUTICALS ($CRVS) Releases Q4 2025 Earnings - Quiver Quantitative
Mon, 09 Mar 2026
Is Corvus Pharmaceuticals (CRVS) Now Attractive After Recent Share Price Volatility? - simplywall.st
Fri, 06 Mar 2026
Corvus Pharmaceuticals (CRVS) hits all-time high on eczema trial results - MSN
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 84 (M) |
| Shares Float | 72 (M) |
| Held by Insiders | 3.5 (%) |
| Held by Institutions | 56.7 (%) |
| Shares Short | 16,050 (K) |
| Shares Short P.Month | 14,880 (K) |
| EPS | -0.53 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.81 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -38.4 % |
| Return on Equity (ttm) | -32.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.52 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -33 (M) |
| Levered Free Cash Flow | -47 (M) |
| PE Ratio | -29.12 |
| PEG Ratio | 0 |
| Price to Book value | 18.81 |
| Price to Sales | 0 |
| Price to Cash Flow | -39.52 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|